Dr. Michael Liebman sits on the scientific advisory board of The Translational and Advanced Medical Center (TAM Center) which is the home of the Cellular Performance Institute (CPI Stem Cells) . He holds a PhD in theoretical chemistry and protein crystallography. He is the Managing Director of IPQ Analytics, LLC and of Strategic Medicine, Inc, and Strategic Medicine, BV (the Hague, NL) after serving as the Executive Director of the Windber Research Institute from 2003-2007. He is also an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery at First Hospital of Wenzhou Medical University. Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center from 2000-2003.
He served as Global Head of Computational Genomics at Roche Pharmaceuticals and Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, and Director of Genomics for Vysis, Inc. He co-founded Prosanos, Inc (now United BioSource) (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics. He serves on 14 scientific advisory boards and is on the Board of Directors and chairs the Science Committee of the Nathaniel Adamczyk Foundation for Pediatric ARDS and is an Advisor to the American Heart Association Science and Technology Accelerator.
Michael is Chair of the Informatics Program of the PhRMA Foundation, Chair of its new program in Translational Medicine and Therapeutics, and a PhRMA Scientific Advisory Board member. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, and the International Park for Translational Biomedicine (Shanghai). He is an Invited Professor at the Shanghai Center for Bioinformatics Technology.
His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life. Recent activities also include computational approaches to disease modeling, patient and disease stratification, drug safety, animal testing reduction, genomic data use in healthcare, and qualitative and quantitative risk assessment in healthcare and the life sciences.
Tune in as Ed Clay and Dr. Michael Liebman sit down to discuss the world of medicine, scientific discovery, and disease. Listeners will hear an in-depth discussion on the state of medical technology, how research is conducted, genomics, and more.
Enjoy this though-provoking episode of The Ed Clay Show with Dr. Michael Liebman!
#medicine #edclayshow #sciencepodcast #genomics
Show Sponsors:
www.beatdownbbq.com/
healthquest365.com/
Timestamps:
00:00:00 - Dr. Michael Liebman’s Scientific Career, Academia vs Industry
00:13:30 - Translational Medicine, Evolution of Science, Data Models
00:25:15 - Genomics, CPI Stem Cells, Future of Diagnostics
00:45:19 - Models for Underserved Communities, Brining Treatment from Mexico to Nashville
01:01:38 - Case Examples, Data Models
01:18:41 - Genomics in the US, Communicating with Patients, Evolution of COVID
01:25:18 - Strategic Plan Moving Forward, Critical Thinking, Artificial Intelligence
30 июл 2024
